MatsukiyoCocokara & Co
TSE:3088
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 028
2 788
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
MatsukiyoCocokara & Co
MatsukiyoCocokara & Co
Revenue
MatsukiyoCocokara & Co
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MatsukiyoCocokara & Co
TSE:3088
|
Revenue
¥1T
|
CAGR 3-Years
23%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
Sundrug Co Ltd
TSE:9989
|
Revenue
¥764.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Tsuruha Holdings Inc
TSE:3391
|
Revenue
¥1T
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Welcia Holdings Co Ltd
TSE:3141
|
Revenue
¥1.2T
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
13%
|
|
|
S
|
Sugi Holdings Co Ltd
TSE:7649
|
Revenue
¥791.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Cosmos Pharmaceutical Corp
TSE:3349
|
Revenue
¥985.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
MatsukiyoCocokara & Co
Glance View
MatsukiyoCocokara & Co., a leading retail and health & beauty chain in Japan, emerges as a compelling player in the consumer goods sector. Born from the merger of Matsumoto Kiyoshi and Cocokara Fine, the company has successfully carved out a niche by providing a wide array of products, ranging from pharmaceuticals to cosmetics, dietary supplements, and lifestyle items. With over 1,000 stores across Japan, often strategically located in urban centers, MatsukiyoCocokara has effectively leveraged the growing trend of health awareness and wellness among consumers. This positioning not only captures the attention of the domestic market but also reflects a keen adaptability to evolving customer preferences, making the brand a staple in contemporary Japanese shopping. Behind its robust storefronts lies a commitment to quality and innovation, with an emphasis on customer-centric service and an expansive online presence bolstered by digital sales channels. The company distinguishes itself through a loyal customer base, driven by its competitive pricing strategy, exclusive product lines, and regular promotions. This diverse portfolio and strong market presence position MatsukiyoCocokara & Co. favorably for future growth, especially as health and wellness continue to dominate consumer interests globally. For investors, the company represents a dynamic opportunity, benefiting from both its established reputation and the potential for expansion in the burgeoning lifestyle enhancement market.
See Also
What is MatsukiyoCocokara & Co's Revenue?
Revenue
1T
JPY
Based on the financial report for Jun 30, 2024, MatsukiyoCocokara & Co's Revenue amounts to 1T JPY.
What is MatsukiyoCocokara & Co's Revenue growth rate?
Revenue CAGR 10Y
8%
Over the last year, the Revenue growth was 6%. The average annual Revenue growth rates for MatsukiyoCocokara & Co have been 23% over the past three years , 12% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet
